

**DESIGN OF A NOVEL COGNITIVE ENHANCER
(8S, 10aS)-8-CARBAMOYL-1,2,3,6,7,8,9,10a-OCTAHYDRO-5H,10H-
PYRROLO[1,2-a][1,4]DIAZOCIN-5,10-DIONE**

Anatoly A. Mazurov*¹, Sergei A. Andronati, Tamara I. Korotenko, Nikolai I. Sokolenko, Alexei I. Dyadenko,
Yuri E. Shapiro, Vitalii Ya. Gorbatyuk, Tatyana A. Voronina.

*Physico-Chemical Institute, National Academy of Sciences, Odessa, Ukraine
Research Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia*

Abstract. A new cognitive enhancer (8S, 10aS)-8-carbamoyl-1,2,3,6,7,8,9,10a-octahydro-5H,10H-pyrrolo[1,2-a][1,4]diazocin-5,10-dione (**3**) has been designed based on the approach consisting of two steps: 1) "obligatory" replacement of histidine with glutamine in TRH; 2) the application of conformational constraints for putative bioactive conformation of [Gln²]-TRH. **3** reversed on 100% electroconvulsive shock-induced amnesia at doses of 0.1 and 1.0 mg/kg and on 83% scopolamine-induced amnesia at a dose of 1 mg/kg, using passive avoidance test. Copyright © 1996 Elsevier Science Ltd

Thyrotropin-releasing hormone (TRH, Gln-His-Pro-NH₂) like many of peptide hormones provoke a wide range of biological responses. In addition to governing the secretion of pituitary hormones such as thyroid stimulating hormone (TSH, thyrotropin) and prolactin, TRH has been characterized as CNS-activating substance functioning either as a neurotransmitter or as a facilitative neuromodulator¹. In particular, TRH facilitates cholinergic and monoaminergic neurotransmission² independently of its hormonal effect³. The established cholinergic deficit and resulting cholinergic treatment strategy in Alzheimer's disease and the ability of TRH and its analogs to enhance cognitive performance in behavioral models in animals⁴ suggests, that TRH analogs represent a logical approach to treat cognitive disorders, including those associated with Alzheimer's disease.

For the purpose of rational modification of TRH molecule, we were pursuing an approach based on our assumption about the existence of "obligatory" similar amino acids. As "obligatory" similar amino acids, we considered pairs of amino acids encoded by the same obligatory nucleotides (Table 1). According to the Crick's "wobble hypothesis", the first two codone bases (obligatory nucleotides) make the most significant contribution into the specific encoding in comparison with the third base (facultative nucleotide)⁵. From twenty proteinogenic amino acids, seven pairs of "obligatory" similar amino acids might be elicited. Since obligatory similar amino acids are encoded by the same obligatory nucleotides we hypothesized that they can replace each other with at least preservation of some kinds of biological effects in certain examples. Indeed, there are some natural

¹ Present address: Astra Hässle AB, Medicinal Chemistry Dep., Preclinical R & D, Mölndal, S 431 83, Sweden
FAX: +46 31 776 3710; E-Mail: anatoly.mazurov@hassle.se.astra.com

occurring peptides with similar biological potency and those peptides contain "obligatory" similar amino acids, for example, magainins⁶, growth hormone-releasing factor⁷, calcitonins⁸, angiotensin analogues⁹.

Table 1. "Obligatory" Similarity of Amino Acids

Asp	GAU	GAC	Cys	UGU	UGC
Glu	GAA	GAG	Trp	UGG	
Phe	UUU	UUC	Ile	AUU	AUC
Leu	UUA	UUG	Met	AUG	AUA
	CUA	CUG			
	CUU	CUC			
His	CAU	CAC	Ser	AGU	AGC
Gln	CAA	CAG	Arg	AGA	AGG
				CGA	CGG
				CGU	CGC
Asn	AAU	AAC			
Lys	AAA	AAG			

Earlier, the application of the hypothesis of "obligatory" similar amino acids has been demonstrated for neurohormone MSH release inhibiting factor (Pro-Leu-Gly-NH₂, MIF, melanostatin)^{10,11}. According to the above mentioned hypothesis, the second amino acid of melanostatin leucine was exchanged with phenylalanine. Both of the peptides MIF and [Phe²]-MIF showed similar profile of locomotor activity after intracerebroventricular administration¹². The level of major neurotropic effect of MIF, antidepressant activity, was approximately retained after obligatory replacement of leucine¹⁰.

Analogous "obligatory" replacement of second amino acid histidine by glutamine were undertaken for thyroliberin. Both TRH (1) and [Gln²]-TRH (2) have great conformational similarities (Table 2).

Table 2. Dihedral angles (deg) for amino acid residues in Glp-His-Pro-NH₂ (1) and Glp-Gln-Pro-NH₂ (2) according to NOESY data.

	ϕ_1	ψ_1	ϕ_2	ψ_2	χ^1_2	χ^2_2	ϕ_3	ψ_3
1	120	-30;180	-89;-152	0;170	±125	0;180	-	0
2	120	60;160	-88;152	120	±126	±60;180	-	0

ϕ , ψ , χ^1 , χ^2 - dihedral angles around N-C α , C α -CO, C α -C β and C β -C γ bonds for first, second and third amino acid residues, consequently

Conformations of TRH and Glp-Gln-Pro-NH₂ in (CD₃)₂SO solution were determined using two-dimensional ¹H NMR spectroscopy (δ - J correlated, COSY, and NOESY) in accordance with approach applied for MIF and TRH analogues^{11,13}. Earlier, it was supposed, that TRH takes a conformation with an intramolecular hydrogen bond between the carboxamide hydrogen and α -carbonyl of pyroglutamyl after recognition by receptor¹⁴. 20% of [Gln²]-TRH molecules exist in quasicyclic conformation in solution. Peptide 2 retains anti-amnesic activity of TRH¹⁵.





Figure 1. Transition from putative bioactive conformation of TRH (1) via its "obligatory" similar analog 2 to mimetic 3.

In order to stabilize the putative bioactive conformations of TRH and its "obligatory" similar analog Glp-Gln-Pro-NH₂ with intramolecular hydrogen bonds between C-terminal carboxamide proton and α -carbonyl of pyroglutamyl (Fig. 1), we synthesized mimetic 3 (Scheme 1). (8S, 10aS)-8-carbamoyl-1,2,3,6,7,8,9,10a-octahydro-5H,10H-pyrrolo[1,2-a][1,4]diazocin-5,10-dione 3 has no pyrrolidone fragment, which is important pharmacophore feature for classical nootropic drugs like pyracetam and its analogues. Since histidine residue in TRH was replaced with "obligatory" similar glutamine, side chain moiety of glutamine was incorporated into designed compound 3. Position of carbamoyl group in pyrrolodiazocine ring was determined based on distance between nitrogen atoms of glutamine side chain and proline in minimum-energy conformations of peptide 2¹⁶.

N-Boc-glutamic acid 4 forms with one equivalent of sodium methoxide in the presence of crown ether soluble in organic solvents complex that was converted into N-benzhydrylglycolamide ester 5 at mild conditions¹⁷ using substantial difference in acidity of α - and γ -carboxyl moieties. Reaction of N-protected glutamic acid α -ester 5 with proline was performed by modified method of "salt condensation"¹⁸. Carboxyl function of proline was blocked by transformation into complex of proline sodium salt with 15-crown-5. Solution of the latter in N,N-dimethylformamide was treated by N-*tert*-butoxycarbonyl glutamic acid α -benzhydrylglycolamide ester γ -(N-hydroxysuccinimide) ester to afford dipeptide 6 after neutralization of reaction mixture with acetic acid. In order to form eight-member ring, active ester method was applied. Glutamyl(α -benzhydrylglycolamide ester)-proline N-hydroxysuccinimide ester obtained after deprotection of amino moiety cyclized into pyrrolo[1,2-a][1,4]-diazocine 7. Hydrophobic diphenylmethyl fragment facilitates the isolation and purification of the heterocycle. Meanwhile, benzhydrylglycolamide ester was readily converted into amide 3 by ammonolysis in dioxane to afford the desired compound.



- (i) CH_3ONa , 15-crown-5, $\text{BrCH}_2\text{CONHCHPh}_2$, EtOAc ; (ii) DCC, N-hydroxysuccinimide, THF;
 (iii) H-Pro-ONa 15-crown-5, DMF; (iv) AcOH ; (v) 4N HCl /dioxane; (vi) $i\text{-Pr}_2\text{NEt}$, MeCN;
 (vii) NH_4OH

Scheme 1.

(8S,10aS)-8-carbamoyl-1,2,3,6,7,8,9,10a-octahydro-5H,10H-pyrrolo[1,2-a][1,4]-diazocin-5,10-dione (**3**) was tested for anti-depressant and nooropic effects after intraperitoneal administration. Anti-depressant potency was examined in experimental model of behavioral despair¹⁹. Cognition enhancing activity (nooropic effect) was assessed by passive avoidance test^{20,21} in which amnesia was induced in rats by electroconvulsive shock (ECS) or scopolamine. Aniracetam, which is considered to be one of major enhancers of cognitive functions, was applied as a reference compound.

Results of forced swimming test indicate the absence of anti-depressive activity for pyrrolo[1,2-a][1,4]-diazocine **3**²². Meanwhile, significant antiamnesic potency was discovered in the passive avoidance test for this compound. It reversed completely ECS induced amnesia at doses 0.1 ($p < 0.05$) and 1.0 mg/kg ($p < 0.05$). Since amnesic effect of scopolamine have been attributed to a central cholinergic action^{23,24} and cholinergic impairment has associated with the aging of the brain and senile dementia, we evaluated the ability of diazocine **3** to protect rats from scopolamine-induced amnesia in the passive avoidance test. This compound is able to reverse scopolamine-induced amnesia at a level of 83% ($p < 0.01$) at dose 1 mg/kg whereas oxiracetam²⁵ shows

only a 12% reversal of this deficit at the same dose. In the acute hypobaric hypoxia model²⁶, the compound showed antihypoxic activity in the dose of 0.1 mg/kg ($p < 0.05$). The new compounds in neuropharmacological tests²⁷ in mice had no sedative and myorelaxant action, motor impairment and psychomotor activation on CNS.

The obtained results with "obligatory" replacement of amino acids in small biologically active peptide TRH forming quasicyclic conformation, which are stabilized by hydrogen bond, demonstrate the application of proposed approach for purposeful design of new biologically active compounds.

References and Notes

1. Metcalf, G.; Dettmar, P. W. *Lancet* **1981**, *1*, 586.
2. Yarbrough, G. *Life Sci.* **1983**, *33*, 111.
3. Stwertka, S. A.; Vincent, G. P.; Gamzu, E. R.; MacNeil, D. A.; Vederese, A. *Pharmacol. Biochem. Behav.* **1991**, *41*, 145.
4. (a) Yarbrough, G.; Pomara, M. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **1985**, *9*, 285. (b) Miyamoto, M.; Yamazaki, N.; Nagaoka, A.; Nigawa, Y. *Ann. N.Y. Acad. Sci.* **1989**, 508.
5. Crick, F. H. C. *J. Mol. Biol.* **1966**, *19*, 548.
6. Zasloff, M. *Proc. Natl. Acad. Sci. USA* **1987**, *84*, 5449.
7. (a) Guillemín, R.; Brazeau, P.; Böhlen, P.; Esch, F.; Ling, N.; Wehrenberg, W. B. *Science* **1982**, *218*, 585. (b) Spiess, J.; Rivier, J.; Vale, W. *Nature* **1983**, *303*, 532.
8. Potts, Jr., J. T. In *Peptides Hormones*; Parsons, J. A., M. A., B. M., B. Ch. Eds.; University Park Press: Baltimore, London, Tokyo, 1976; p. 134.
9. Schröder, E.; Lübke, K. *The Peptides*, Vol. II; Academic Press: New York and London, 1966; pp. 52.
10. (a) Mazurov, A. A.; Andronati, S. A.; Kabanov, V. M.; Sokolenko, N. I.; Rokachinskaya, M. G.; Shapiro, Yu. E.; Gorbatyuk, V. Ya. *Collect. Czech. Chem. Commun.* **1990**, *55*, 2555. (b) Rokachinskaya, M. G.; Golovenko, N. Ya.; Kabanov, V. M.; Mazurov, A. A.; Andronati, S. A. *Physiologically Active Compounds (Kiev)* **1991**, *23*, 46.
11. Shapiro, Yu. E.; Gorbatyuk, V. Ya.; Kabanov, V. M.; Mazurov, A. A.; Andronati, S. A.; Lobasyuk, B. A.; Golovenko, N. Ya.; Rokachinskaya, M. G. *Sov. J. Bioorg. Chem.* **1990**, *16*, 1607.
12. Mazurov, A. A.; Andronati, S. A.; Lobasyuk, B. A.; Kabanov, V. M.; Korotenko, T. I. *Pharm. Chem. J.* **1988**, 155.
13. Gorbatyuk, V. Ya.; Shapiro, Yu. E.; Mazurov, A. A.; Zhuravlyov, V. G.; Andronati, S. A.; Korotenko, T. I.; Romanovsky, P. Ya. *Sov. J. Bioorg. Chem.* **1992**, *18*, 235.
14. Peterson, R. E.; Guillemín, R. G. *Amer. J. Med.* **1974**, *57*, 591.
15. TRH reversed ECS-induced amnesia on 23% in the dose of 0.1 mg/kg, while **2** was equipotent in the dose of 1 mg/kg.
16. Interatomic distances $N^{\alpha}_{Pro} - N^{\delta}_{Gln}$ is 5–6 Å for **2** and $N^4 - N_{carbamoyl}$ is 5.5 Å for **3**.
17. Mazurov, A. A.; Antonenko, S. V.; Andronati, S. A. *Chemistry of Natural Compounds (USSR)* **1986**, 208.

18. (a) Andronati, S. A.; Mazurov, A.A. *Sov. J. Bioorg. Chem.* **1984**, *10*, 1445. (b) Andronati, S. A.; Mazurov, A.A.; Korotenko, T. I. *Chemistry of Peptides and Proteins* **1986**, *3*, 37.
19. Porsolt, R. D.; Anton, G.; Blavet, N.; Jalfre, M. *Eur. J. Pharmacol.* **1978**, *47*, 379.
20. Banfi, S.; Cornelli, U.; Fonio, W.; Dorigotti, L. *J. Pharmacol. Methods* **1982**, *8*, 255.
21. Pozzi, O.; Allievi, E.; Biagetti, R.; Banfi, S.; Dorigotti, L. *Pharmacol. Res. Commun.* **1988**, *20* (Suppl. 2), 315.
22. No statistically significant differences between control and experiment were revealed at doses 1.0 - 0.001 mg/kg.
23. Schindler, U.; Rush, D. K.; Fielding, S. *Drugs Develop. Res.* **1984**, *4*, 567.
24. Verloes, R.; Scotto, A. M.; Gobert, J.; Wülfert, E. *Psychopharmacology* **1988**, *95*, 226.
25. Pinza, M.; Farina, C.; Cerri, A.; Pfeiffer, U.; Riccaboni, M. T.; Banfi, S.; Biagetti, R.; Pozzi, O.; Magnani, M.; Dorigotti, L. *J. Med. Chem.* **1993**, *36*, 4214.
26. Antihypoxic effect was studied using the model of acute hypobaric hypoxia in flowthrough low pressure chamber model (Korablyov, M. V.; Lukienko, P. I. *Antihypoxic Compounds*; 1976, Minsk, Naukova Dumka, p.334). Experiments were carried out on male rats. The animals in experimental group (16 rats) were administered (ip) solution of the compound at 10 min before experiment. The animals in control group (16 rats) were injected saline. Groups of 4 animals were "lifted" with the speed 1 km/min to the platform with the "height" of 11 km. Animals were kept on this platform for 15 min and then put down with the speed 3.7 km/min. Ascent to high altitude was simulated experimentally by exposure of rats in chamber to a breathing air at alterable pressure. 56% of animals survived in experimental group in comparison with 18% in control group.
27. For detection of neurological deficit, myorelaxant and sedative action, motor impairment, psychomotor activation were investigated in rolling roller test (Dunham, N. W.; Miya, T. S. *J. Amer. Pharm. Assoc.* **1957**, *46*, 208), traction test (Boissier, J.-R.; Dumont, C.; Ratouis, R.; Pagny, J. *Arch. Int. Pharmacodyn.* **1961**, *133*, 29) and open field test (Boissier, J.-R.; Simon, P. *Thérapie* **1962**, *17*, 1225).

(Received in Belgium 26 July 1996; accepted 4 October 1996)